Centogene (CNTG) announced the discovery of a new small molecule together with Evotec SE (EVO). The new molecule has the potential to treat patients with type 2 and type 3 Gaucher disease, otherwise known as neuronopathic Gaucher disease. The discovery has been the result of the collaborative work under the existing drug discovery partnership which has been in place since 2020. The Companies have now extended this collaboration for another year, granting Evotec an R&D License for the continued development activities. The amended agreement also provides Evotec with an exclusive option until March 31, 2025, to determine whether to enter a license agreement acquiring CENTOGENE’s share of the IP generated throughout the collaboration. In exchange for such a global exclusive license, CENTOGENE would receive an up-front fee, milestone payments, as well as additional royalties. Further financial details were not disclosed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTG:
- Centogene’s Biodatabank Drives Rare Disease Breakthroughs
- Centogene Biodatabank grows to incorporate insights from over 850K patients
- CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
- Centogene N.V. Explores Financial Strategies
- Centogene receives noncompliance notification from Nasdaq